US20050249732A1 - Cytokine production-inducing antibody - Google Patents
Cytokine production-inducing antibody Download PDFInfo
- Publication number
- US20050249732A1 US20050249732A1 US10/527,665 US52766505A US2005249732A1 US 20050249732 A1 US20050249732 A1 US 20050249732A1 US 52766505 A US52766505 A US 52766505A US 2005249732 A1 US2005249732 A1 US 2005249732A1
- Authority
- US
- United States
- Prior art keywords
- antibody
- cells
- antibodies
- receptor
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000001939 inductive effect Effects 0.000 title abstract description 9
- 230000016396 cytokine production Effects 0.000 title 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims abstract description 55
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims abstract description 55
- 102000004127 Cytokines Human genes 0.000 claims abstract description 37
- 108090000695 Cytokines Proteins 0.000 claims abstract description 37
- 239000012636 effector Substances 0.000 claims abstract description 36
- 238000000034 method Methods 0.000 claims abstract description 23
- 239000000427 antigen Substances 0.000 claims abstract description 17
- 102000036639 antigens Human genes 0.000 claims abstract description 17
- 108091007433 antigens Proteins 0.000 claims abstract description 17
- 230000004913 activation Effects 0.000 claims abstract description 16
- 239000012429 reaction media Substances 0.000 claims abstract description 11
- 210000000987 immune system Anatomy 0.000 claims description 13
- 102000000588 Interleukin-2 Human genes 0.000 abstract description 37
- 108010002350 Interleukin-2 Proteins 0.000 abstract description 37
- 208000023275 Autoimmune disease Diseases 0.000 abstract description 3
- 102000015696 Interleukins Human genes 0.000 abstract description 3
- 108010063738 Interleukins Proteins 0.000 abstract description 3
- 206010028980 Neoplasm Diseases 0.000 abstract description 3
- 230000001363 autoimmune Effects 0.000 abstract description 3
- 208000015181 infectious disease Diseases 0.000 abstract description 3
- 208000027866 inflammatory disease Diseases 0.000 abstract description 3
- 229940047122 interleukins Drugs 0.000 abstract description 3
- 244000052769 pathogen Species 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 85
- 230000028327 secretion Effects 0.000 description 30
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 28
- 210000003743 erythrocyte Anatomy 0.000 description 26
- 210000000822 natural killer cell Anatomy 0.000 description 18
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 17
- 238000003556 assay Methods 0.000 description 14
- 238000004519 manufacturing process Methods 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 239000006228 supernatant Substances 0.000 description 11
- 238000011534 incubation Methods 0.000 description 9
- 210000005087 mononuclear cell Anatomy 0.000 description 9
- 229940053819 winrho Drugs 0.000 description 8
- 108010073807 IgG Receptors Proteins 0.000 description 7
- 206010035226 Plasma cell myeloma Diseases 0.000 description 7
- 150000004676 glycans Chemical class 0.000 description 7
- 201000000050 myeloid neoplasm Diseases 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 6
- 108060003951 Immunoglobulin Proteins 0.000 description 6
- 102000018358 immunoglobulin Human genes 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 230000009261 transgenic effect Effects 0.000 description 6
- 108090001005 Interleukin-6 Proteins 0.000 description 5
- 102000004889 Interleukin-6 Human genes 0.000 description 5
- 241001529936 Murinae Species 0.000 description 5
- 108090000526 Papain Proteins 0.000 description 5
- 239000004365 Protease Substances 0.000 description 5
- 230000006037 cell lysis Effects 0.000 description 5
- 230000009089 cytolysis Effects 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 229940072221 immunoglobulins Drugs 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 229940055729 papain Drugs 0.000 description 5
- 235000019834 papain Nutrition 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 4
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 4
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 4
- 108090000174 Interleukin-10 Proteins 0.000 description 4
- 102000003814 Interleukin-10 Human genes 0.000 description 4
- 108090001007 Interleukin-8 Proteins 0.000 description 4
- 102000004890 Interleukin-8 Human genes 0.000 description 4
- 108700012920 TNF Proteins 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 108010087819 Fc receptors Proteins 0.000 description 3
- 102000009109 Fc receptors Human genes 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000020411 cell activation Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 229940126601 medicinal product Drugs 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 description 2
- 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 description 2
- 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 description 2
- 102000009490 IgG Receptors Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 108010002386 Interleukin-3 Proteins 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 108010002616 Interleukin-5 Proteins 0.000 description 2
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 description 2
- 108010002586 Interleukin-7 Proteins 0.000 description 2
- 108010002335 Interleukin-9 Proteins 0.000 description 2
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 2
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 2
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 2
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- -1 etc. Proteins 0.000 description 2
- 230000033581 fucosylation Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 150000002704 mannoses Chemical class 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 230000009450 sialylation Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102100027544 Blood group Rh(D) polypeptide Human genes 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102000030902 Galactosyltransferase Human genes 0.000 description 1
- 108060003306 Galactosyltransferase Proteins 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000580024 Homo sapiens Blood group Rh(D) polypeptide Proteins 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- YJQCOFNZVFGCAF-UHFFFAOYSA-N Tunicamycin II Natural products O1C(CC(O)C2C(C(O)C(O2)N2C(NC(=O)C=C2)=O)O)C(O)C(O)C(NC(=O)C=CCCCCCCCCC(C)C)C1OC1OC(CO)C(O)C(O)C1NC(C)=O YJQCOFNZVFGCAF-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000035409 positive regulation of cell proliferation Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000006333 protein structural change Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 1
- ZHSGGJXRNHWHRS-VIDYELAYSA-N tunicamycin Chemical compound O([C@H]1[C@@H]([C@H]([C@@H](O)[C@@H](CC(O)[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C(NC(=O)C=C2)=O)O)O1)O)NC(=O)/C=C/CC(C)C)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O ZHSGGJXRNHWHRS-VIDYELAYSA-N 0.000 description 1
- MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/34—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
Definitions
- the present invention relates to a method for measuring the activation of an effector cell belonging to the immune system, or modified in vitro, by means of a monoclonal (MoAb) or polyclonal antibody, characterized in that it comprises bringing CD16 receptor-expressing cells into contact in a reaction medium in the presence of the antibody and of the antigen for said antibody, and measuring the amount of at least one cytokine produced by the CD16 receptor-expressing cell.
- the invention also relates to the selection of antibodies having the characteristic of inducing the expression of cytokines and of interleukins, in particular IFN ⁇ or IL2.
- Immunotherapy by means of polyclonal or monoclonal antibodies is in the process of becoming one of the most important aspects of medicine.
- the results obtained in clinical trials appear to be contrasting.
- the monoclonal antibody may prove to be insufficiently effective.
- Today, research is directed toward the immunoglobulin Fc ⁇ fragment in order to improve antibody properties. In the end, this should make it possible to obtain antibodies which interact with and activate the receptors of effector cells (macrophage, T lymphocyte and NK cell).
- the biological activity of certain immunoglobulins G is dependent on the structure of the oligosaccharides present on the molecule, and in particular on its Fc portion.
- the IgG molecules of all human and murine subclasses have an N-oligosaccharide attached to the CH 2 domain of each heavy chain (at residue Asn 297 for human IgGs). The influence of this glycan residue on the ability of the antibody to interact with effector molecules (Fc receptors and complement) has been demonstrated.
- the problem is therefore to determine the ability of a given antibody to stimulate the production of cytokines by effector cells, and the consequences of such an activation according to the nature of the cytokines released.
- the invention therefore proposes the use of antibodies selected using a Jurkat CD16 test, by measuring secreted IL2 or other cytokines, which makes it possible to guarantee the biological activity of said antibodies for therapeutic use.
- the present invention relates to a method for measuring the activation of an effector cell belonging to the immune system, which may or may not be transformed, by means of a monoclonal (MoAb) or polyclonal antibody characterized in that it comprises bringing CD16 receptor-expressing cells into contact in a reaction medium in the presence of the antibody and of the antigen for said antibody, and measuring the amount of at least one cytokine produced by the CD16 receptor-expressing cell.
- a monoclonal (MoAb) or polyclonal antibody characterized in that it comprises bringing CD16 receptor-expressing cells into contact in a reaction medium in the presence of the antibody and of the antigen for said antibody, and measuring the amount of at least one cytokine produced by the CD16 receptor-expressing cell.
- transformed cell is intended to mean a cell that has been genetically modified so as to express a receptor, in particular the CD16 receptor.
- a Jurkat-type line or another line transfected with an expression vector encoding the Fc receptor, including CD16, CD32 and CD64, as effector cell Preferably, a Jurkat line transfected with an expression vector encoding the CD16 receptor is used as effector cell.
- This line is particularly advantageous since it is immortalized and develops indefinitely in culture media.
- cytokines that may be quantified, it is possible to measure the production of at least one cytokine selected from IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, etc., TNFa, TGF ⁇ , IP10 and IFN ⁇ .
- the interleukin IL-2 may advantageously be chosen.
- the amount of cytokine produced is a marker for activation or for inhibition of effector cells.
- the amount of interleukin IL2 secreted reflects the quality of the antibody bound by the CD16 receptor as regards its antigen-binding integrity (Fc function) and effectiveness (antigenic site).
- the measurement of the amount of IL2 is correlated with an ADCC-type activity.
- the invention in another aspect, relates to a method for evaluating the effectiveness of a monoclonal or polyclonal antibody, characterized in that it comprises bringing CD16 receptor-expressing effector cells of the immune system, which may or may not be transformed, into contact in a reaction medium in the presence of an antibody and of the antigen for said antibody, and measuring the amount of at least one cytokine produced by the CD16 receptor-expressing cell.
- This method is particularly suitable for evaluating the effectiveness of a monoclonal or polyclonal antibody having an anti-human red blood cell Rh D specificity.
- the invention in another aspect, relates to a method for evaluating the ability of a cell to produce an effective monoclonal antibody, characterized in that it comprises bringing CD16 receptor-expressing effector cells of the immune system, which may or may not be transformed, into contact in a reaction medium in the presence of an antibody and of the antigen for said antibody, and measuring the amount of at least one cytokine produced by the CD16 receptor-expressing cell.
- This method can be implemented for cells used for the production of therapeutic antibodies, such as CHO, YB2/0, human lymphoblastoid cells, insect cells and murine myeloma cells.
- This method may also be applied to the evaluation of MoAb production by transgenic plants or transgenic mammals.
- the invention is directed toward a method for evaluating the effectiveness and the integrity of polyclonal antibodies after one or more purification steps, characterized in that it comprises bringing CD16 receptor-expressing effector cells of the immune system, which may or may not be transformed, into contact in a reaction medium in the presence of the purified antibody and of the antigen for said antibody, and measuring the amount of at least one cytokine produced by the CD16 receptor-expressing cell.
- IVIgs human immunoglobulins
- antibodies for which an increase of more than 100%, 250%, 500% or 1000% in the amount of IL-2 release is observed compared with the control in the absence of antibody, or a given antibody as negative reference, will be selected.
- the invention is also directed toward the use of the method described above, for selecting antibodies that are effective for a therapeutic treatment.
- the antibody selected may be an anti-D. It may also be intended for the treatment of autoimmune and inflammatory diseases, cancers and infections with pathogenic agents.
- the invention also relates to a kit for evaluating the biological activity of an antibody, comprising means and reagents required and CD16 receptor-expressing effector cells for carrying out the method described above making it possible to assay at least one cytokine, in particular IL-2, IFN and TNF.
- a kit for evaluating the biological activity of an antibody comprising means and reagents required and CD16 receptor-expressing effector cells for carrying out the method described above making it possible to assay at least one cytokine, in particular IL-2, IFN and TNF.
- this assay may also comprise an ADCC assay.
- the invention relates to a method for selecting an optimized chimeric, humanized or human monoclonal antibody, characterized in that it comprises bringing CD16 receptor-expressing cells into contact in a reaction medium in the presence of the antibody and of the antigen for said antibody, and measuring the amount of at least one cytokine produced by the CD16 receptor-expressing cell.
- the antibody of the invention is capable of inducing the secretion of at least one cytokine by a leukocytic cell, in particular of the NK (natural killer) family, or by cells of the monocyte-macrophage group.
- a leukocytic cell in particular of the NK (natural killer) family
- cells of the monocyte-macrophage group for selecting the antibodies, use is made of a Jurkat-type line or another line transfected with an expression vector encoding the Fc receptor, including CD16, CD32 and CD64, as effector cell.
- a Jurkat line transfected with an expression vector encoding the CD16 receptor is used as effector cell. This line is particularly advantageous since it is immortalized and develops indefinitely in culture media.
- the amount of interleukin IL2 secreted reflects the quality of the antibody bound by the CD16 receptor as regards its antigen-binding integrity (Fc function) and effectiveness (antigenic site).
- the optimized antibody can be prepared after having been purified and/or modified ex vivo by modification of the glycan structure of the Fc fragment.
- any suitable chemical, chromatographic or enzymatic means can be used to modify the glycan structure of the antibodies.
- the antibody can be produced by cells of rat myeloma lines, in particular YB2/0 and its derivatives. Other lines may be selected for their properties of producing the antibodies defined above.
- Human lymphoblastoid cells, insect cells and murine myeloma cells may, for example, be tested.
- the selection may also be applied to the evaluation of the antibodies produced by transgenic plants or transgenic mammals.
- production in CHO serves as a reference (CHO being used for medicament antibody production) for comparing and selecting the production systems resulting in the antibodies according to the invention.
- the general glycan structure of antibodies is of the biantennary type, with short chains, a low degree of sialylation, nonintercalated terminal attachment point mannoses and GlcNAcs, and a low degree of fucosylation.
- the intermediate GlcNAc content is non zero.
- These compositions can be obtained with rat myeloma lines, for example with the YB2/0 line.
- the invention is directed toward the use of an antibody described above, for preparing a medicament intended to induce the secretion of at least one cytokine by an effector cell belonging to the immune system, said antibody being characterized in that it can be obtained by means of a method of selection comprising bringing CD16 receptor-expressing effector cells of the immune system, which may or may not be transformed, into contact in a reaction medium in the presence of the test antibody and of the antigen for said antibody, and measuring the amount of at least one cytokine produced by the CD16 receptor-expressing cell.
- a Jurkat line transfected with an expression vector encoding the CD16 receptor is used as effector cell.
- Said released cytokines are interleukins, interferons and tissue necrosis factors (TNF).
- TNF tissue necrosis factors
- the antibody selected has the ability to induce the secretion of at least one cytokine chosen from IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, etc., TNFa, TGF ⁇ , IP10 and IFN ⁇ , by the CD16 receptor-expressing effector cells of the immune system.
- the antibody selected has the ability to induce the secretion of IL-2 by the CD16 receptor-expressing effector cells of the immune system.
- the amount of interleukin IL2 secreted reflects the quality of the antibody bound by the CD16 receptor as regards its antigen-binding integrity (Fc function) and effectiveness (antigenic site).
- the measurement of the amount of IL2 is correlated with an ADCC-type activity.
- the selection can take place on antibodies produced by cells commonly used for the production of therapeutic antibodies, such as CHO, YB2/0, human lymphoblastoid cells, insect cells and murine myeloma cells.
- the selection may also be applied to the evaluation of antibodies produced by transgenic plants or transgenic mammals.
- the invention is directed toward the use of an antibody produced by a rat myeloma line, for example with the YB2/0 line, for preparing a medicinal product intended to induce the secretion of at least one cytokine by an effector cell belonging to the immune system.
- the invention relates to the use of an antibody having a biantennary-type glycan structure, with short chains, a low degree of sialylation, nonintercalated terminal attachment point mannoses and GlcNAcs and a low degree of fucosylation, for preparing a medicinal product intended to induce the secretion of at least one cytokine by an effector cell belonging to the immune system.
- the intermediate GlcNAc content is non zero.
- the antibody selected is capable of inducing the secretion of at least one cytokine by a leukocytic cell, in particular of the NK (natural killer) family, or by cells of the monocyte-macrophage group.
- the invention also relates to the use of the selected antibodies described above that are specific for an antigen which originates from a pathological cell or from an organism that is pathogenic for humans.
- This antibody is a monoclonal or polyclonal antibody.
- the antibody is a monoclonal or polyclonal antibody having anti-human red blood cell Rhesus specificity.
- the antibody according to the invention may also be an antibody directed against viruses that are pathogenic for humans, against malignant tumor antigens or against the antigens of a bacterium or of a parasite that is pathogenic for humans.
- the antibody selected shows an increase of more than 100%, 250%, 500% or 1000% in the amount of IL-2 release compared with the control in the absence of antibody or in the presence of a given antibody as negative reference.
- the method described above can optionally be carried out in the presence of human immunoglobulins (IVIgs).
- IVIgs human immunoglobulins
- homologous antibodies produced in CHO cells, or else commercially available reference antibodies may be used.
- the invention is directed toward the use of said selected antibodies as a therapeutic support in human medicine, in particular for producing a medicinal product intended for the treatment of autoimmune and inflammatory diseases, cancers and infections with pathogenic agents.
- FIG. 1 Description of the MNC ADCC assay
- Mononuclear cells in the presence of Tegeline (IVIg) are incubated with the anti-Rhesus D antibodies and Rhesus+red blood cells (target). After an overnight period at 37° C., the red blood cell lysis is measured by evaluating the amount of hemoglobin released into the reaction medium.
- FIG. 2 Description of the NK ADCC assay
- Purified NK cells are incubated with the anti-Rhesus D antibodies and Rhesus+red blood cells (target). After an overnight period at 37° C., the red blood cell lysis is measured by evaluating the amount of hemoglobin released into the reaction medium.
- FIG. 3 NK ADCC results and inhibition with the anti-CD16 “3G8”
- the anti-D antibodies DF5-EBV (expressed by the EBV-immortalized B cell) and DF5-YB2/0 (expressed by the YB2/0 cell) are compared with the polyclonal antibody WinRho with respect to their ability to induce lysis of Rhesus D red blood cells in the presence of NK cells.
- the inhibition of the ADCC is studied in the presence of the anti-CD16 3G8.
- FIG. 4 Description of the Jurkat CD16 assay
- Jurkat CD16 cells are mixed with various anti-D antibodies in the presence of Rhesus+red blood cells and of PMA. After an overnight incubation period, the release of IL-2 into the supernatant is quantified by ELISA.
- FIG. 5 Results of the Jurkat CD16 assay
- the antibodies that are positive in ADCC-NK induce secretion of IL2 in the presence of Jurkat CD16 and of their target.
- FIG. 6 Release of cytokine (IL-2, IFN and TNF) by leukocytes that are antibody-activated in the presence of their target
- FIG. 7 Release of cytokine (IFN, TNF) by NK cells that are antibody-activated in the presence of their target (LFB-R297-RBC)
- B—Purified NK cells were mixed with various anti-D antibodies in the presence of Rhesus+red blood cells. After an overnight incubation period, the release of TNFa and of IFN ⁇ into the supernatant was quantified by ELISA.
- FIG. 8 Release of IL2 by Jurkat CD16 activated by an anti-CD20
- B—Jurkat CD16 cells were mixed with various anti-CD20 antibodies (murine antibody CAT13 and chimeric antibody C273) in the presence of Raji cells and of PMA. After an overnight incubation period, the release of IL-2 into the supernatant was quantified by ELISA.
- FIG. 9 Release of IL2 by Jurkat CD16 activated by an anti-D
- B—Jurkat CD16 cells were mixed with various anti-D antibodies in the presence of Rhesus+red blood cells and of PMA. After an overnight incubation period, the release of IL-2 into the supernatant was quantified by ELISA.
- DF5 expressed in YB2/0 and T125 expressed in CHO Lec13 induce strong secretion of IL2.
- FIG. 10 Line of correlation between the ADCC (Tegeline 500 ⁇ g/well and anti-D at 7.5 ng/well) and the Jurkat IL2 assay.
- FIG. 11 Secretion of IL-8 by mononuclear cells.
- FIG. 12 Induction of TNF alpha, IL-6 and TGF beta secretion by mononuclear cells.
- FIG. 13 Induction of cytokine secretion by polymorphonuclear cells.
- FIG. 14 Induction of IFN gamma, TNF alpha and IP10 secretion by NK cells.
- WinRho polyclonal antibodies DF5-EBV monoclonal antibody, DF5-YB2/0 monoclonal antibody.
- This assay evaluates the ability of the anti-D antibodies to bind to the CD16 receptor (Fc gamma RIII) expressed on Jurkat CD16 cells, and to induce IL2 secretion.
- This assay consists in bringing the following into contact in a 96-well plate: the anti-D antibodies, the papain-treated Rhesus-positive red blood cells, the Jurkat CD16 cells and PMA.
- the 96-well plates are centrifuged and the amount of secreted IL2 is assayed in the supernatant.
- Positive control antibodies Poly-D WinRho, DF5-YB2/0.
- Negative control antibody DF5.
- IL2 assay kit Quantikine from R/D.
- the values (in pg/ml) are given in the form of a histogram for each sample.
- the Mab DF5-EBV was produced by human B lymphocytes obtained from a D-negative immunized donor, and immortalized by transformation with EBV. This antibody was used as a negative control given that it was shown to be incapable of eliminating Rhesus-positive red blood cells from the circulation in a clinical trial.
- the monoclonal antibody (Mab) DF5-YB2/0 was obtained by expressing the primary sequence of DF5-EBV in the YB2/0 line.
- the monoclonal antibody R297 and other recombinant antibodies were also expressed in YB2/0.
- a third series of experiments showed the value of an in vitro assay using Jurkat CD16 cells to evaluate the effectiveness of anti-D antibodies.
- the antibodies were incubated overnight with Rhesus-positive red blood cells and Jurkat CD16 cells.
- the release of IL-2 into the supernatant was evaluated by ELISA.
- a strong correlation between ADCC and activation of the Jurkat cells was observed, which implies that this assay can be used to discriminate between anti-D antibodies as a function of their reactivity toward FcgammaRIII (CD16).
- IL2 induces activation of T lymphocytes and of the NK cells themselves, which can go as far as stimulation of cell proliferation.
- IFN ⁇ stimulates the activity of CTLs and can enhance the activity of macrophages.
- TNF stimulates the proliferation of tumor-infiltrating lymphocytes and macrophages.
- IL-1Ra is a cytokine produced by macrophages which compete with IL1 at the level of its receptor and thus exerts an anti-inflammatory effect.
- IL10 is a molecule that inhibits the activation of various effector cells and the production of cytokines.
- cytokine syntheses are dependent on the presence of the target. There are few differences in the cytokine profiles induced by the antibody R297 and the polyclonal anti-D antibody. AD1 very often does not induce cytokine secretion.
- the monoclonal antibody R297 and the polyclonal antibody WinRho induce considerable secretion of IL8 in the presence of mononuclear cells. This secretion is dependent on the antibody concentration and on the presence of the antigenic target.
- the antibody AD1 is much less effective ( FIG. 11 ), i.e. less capable of inducing the production of cytokines.
- the monoclonal antibody R297 and the polyclonal antibody WinRho induce considerable secretion of TNF alpha, and, to a lesser degree, although greater than AD1, secretion of IL6, of IFN gamma, of IP10, of TNF alpha and of TGF beta.
- this secretion of IL6, IFN gamma and IP10 increases, but it decreases for TNF alpha and TGF beta ( FIG. 12 ).
- the monoclonal antibody R297 and the polyclonal antibody WinRho induce a very weak, but greater than AD1, secretion of IL2, of IFN gamma, of IP10 and of TNF by polymorphonuclear cells. This secretion is antibody-concentration dependent ( FIG. 13 ).
- the monoclonal antibody R297 and the polyclonal antibody WinRho induce considerable secretion of IFN gamma, of IP10 and of TNF by NK cells. This secretion is antibody-concentration dependent ( FIG. 14 ).
- Anti-CD20 the chimeric anti-CD20 antibody transfected into YB2/0 is compared with a commercial anti-CD20 antibody produced in CHO (Rituxan).
- Anti-HLA-DR the same sequence encoding the chimeric anti-HLA-DR antibody is transfected into CHO (B11) or YB2/0 (4B7).
- Target cells Raji cells expressing at their surface the CD20 and HLA-DR antigens.
- Effector cells human NK cells purified by negative selection from a human blood bag.
- anti-CD20 or anti-HLA-DR antibodies are incubated with Raji cells (targets) and NK cells (effectors). After incubation for 16 hours, the cells are centrifuged. The supernatants are assayed for TNF alpha and IFN gamma.
- TNF alpha The results are expressed in pg/ml of TNF alpha assayed in the supernatants. The various concentrations of antibodies added to the reaction mixture are given along the X-axis ( FIG. 15 ).
- the chimeric anti-CD20 and anti-HLA-DR antibodies produced in YB2/0 induce higher levels of TNF in the presence of their target (Raji) compared with the same antibodies produced in CHO.
- the amount of TNF alpha is clearly dose-dependent on the concentration of antibody added. At 10 mg/ml of antibody, five times more TNF alpha is induced with the antibodies produced in YB2/0 compared with the antibodies produced in CHO.
- IFN gamma The results are expressed in pg/ml of IFN gamma assayed in the supernatants. The various concentrations of antibodies added to the reaction mixture are given along the X-axis ( FIG. 16 ).
- the chimeric anti-CD20 and anti-HLA-DR antibodies produced in YB2/0 induce higher levels of IFN gamma in the presence of their target (Raji) compared with the same antibodies produced in CHO.
- the amount of IFN gamma is clearly dose-dependent on the concentration of antibody added.
- the anti-HLA-DR antibody produced in CHO induces no secretion of IFN gamma, whereas 40 ng/ml of the antibody produced in YB2/0 induces approximately 1000 pg/ml of IFN gamma.
- the anti-CD20 antibody less than 10 ng/ml of the antibody produced in YB2/0, and 200 ng/ml of the antibody produced in CHO, are required to induce 300 pg/ml of IFN gamma ( FIG. 16 ).
Abstract
Description
- The present invention relates to a method for measuring the activation of an effector cell belonging to the immune system, or modified in vitro, by means of a monoclonal (MoAb) or polyclonal antibody, characterized in that it comprises bringing CD16 receptor-expressing cells into contact in a reaction medium in the presence of the antibody and of the antigen for said antibody, and measuring the amount of at least one cytokine produced by the CD16 receptor-expressing cell. The invention also relates to the selection of antibodies having the characteristic of inducing the expression of cytokines and of interleukins, in particular IFNγ or IL2.
- Immunotherapy by means of polyclonal or monoclonal antibodies is in the process of becoming one of the most important aspects of medicine. On the other hand, the results obtained in clinical trials appear to be contrasting. In fact, the monoclonal antibody may prove to be insufficiently effective. Today, research is directed toward the immunoglobulin Fcγ fragment in order to improve antibody properties. In the end, this should make it possible to obtain antibodies which interact with and activate the receptors of effector cells (macrophage, T lymphocyte and NK cell).
- The biological activity of certain immunoglobulins G is dependent on the structure of the oligosaccharides present on the molecule, and in particular on its Fc portion. The IgG molecules of all human and murine subclasses have an N-oligosaccharide attached to the CH2 domain of each heavy chain (at residue Asn 297 for human IgGs). The influence of this glycan residue on the ability of the antibody to interact with effector molecules (Fc receptors and complement) has been demonstrated. Inhibiting glycosylation of a human IgG1, by culture in the presence of tunicamycin, results for example in a 50-fold decrease in the affinity of this antibody for the FcγR1 receptor present on monocytes and macrophages (Leatherbarrow et al., 1985). Binding to the FcγRIII receptor is also affected by the loss of carbohydrates on IgG, since it has been described that an unglycosylated IgG3 is incapable of inducing ADCC-type lysis by the FcγRIII receptor on NK cells (Lund et al., 1990).
- However, beyond the necessary presence of these glycan residues, it is more precisely the heterogeneity of their structure which can result in differences in the ability to engage effector functions. Galactosylation profiles that are variable according to individuals (human serum IgG1s) have been observed. These differences probably reflect disparities between the activity of galactosyltransferases and other enzymes between the cellular clones of these individuals (Jefferis et al., 1990). Although this normal heterogeneity of post-translational processes generates various glycoforms (even in the case of monoclonal antibodies), it can result in atypical structures associated with certain pathological states such as rheumatoid arthritis or Crohn's disease, for which a considerable proportion of agalactosylated residues has been demonstrated (Parekh et al., 1985).
- Faced with the complexity posed by the relationship that exists between the various glycan structures and the activity of antibodies, it would be useful to be able to rapidly discriminate which antibodies are effective, and thus make it possible to select cell lines producing antibodies having greater effectiveness or specific properties in the activation or inhibition of certain components of the immune system.
- In application FR 0004685 of Apr. 12, 2000 (LFB), we have described a novel method for preparing a monoclonal antibody capable of activating effector cells expressing FcγRIII. In this method, monoclonal antibodies originating from hybridomas or from transfected lines are tested in a reaction mixture comprising the target cells of said antibodies, effector cells comprising FcγRIII-expressing cells, and polyvalent IgGs. Thus, it is possible to determine the percentage lysis of the target cells and to select monoclonal antibodies which activate the effector cells, causing significant lysis of the target cells (FcγRIII-type ADCC activity). For example, the Fab portion of the anti-D antibody will bind to the Rhesus D antigen carried by red blood cells. Subsequent to this binding, its Fc portion then binds to the Fc gamma RIII receptor, or CD16, of the effector cell (NK cell). This “sandwich” induces the secretion of chemical substances such as performs which will lyse the red blood cell. This is therefore an antibody-dependent cellular cytotoxicity (ADCC). In order to be close to physiological conditions, the test is carried out in the presence of human polyvalent immunoglobulins.
- In the context of the invention, it has been found that the binding of an antibody to its ligand can induce activation of CD16-transfected Jurkat cells, inducing IL2 secretion. A strong correlation is observed between the secretion of IL2 by Jurkat CD16 and the CD16-mediated ADCC activity of the effector cells. In addition, we have observed that the same antibody directed against a given antigen is completely ineffective when it is produced in mouse myeloma lines, whereas it is found to be very effective when it is produced in other cell lines.
- The problem is therefore to determine the ability of a given antibody to stimulate the production of cytokines by effector cells, and the consequences of such an activation according to the nature of the cytokines released.
- The invention therefore proposes the use of antibodies selected using a Jurkat CD16 test, by measuring secreted IL2 or other cytokines, which makes it possible to guarantee the biological activity of said antibodies for therapeutic use.
- Thus, in a first aspect, the present invention relates to a method for measuring the activation of an effector cell belonging to the immune system, which may or may not be transformed, by means of a monoclonal (MoAb) or polyclonal antibody characterized in that it comprises bringing CD16 receptor-expressing cells into contact in a reaction medium in the presence of the antibody and of the antigen for said antibody, and measuring the amount of at least one cytokine produced by the CD16 receptor-expressing cell.
- The term “transformed cell” is intended to mean a cell that has been genetically modified so as to express a receptor, in particular the CD16 receptor.
- In general, for selecting the antibodies, use is made of a Jurkat-type line or another line transfected with an expression vector encoding the Fc receptor, including CD16, CD32 and CD64, as effector cell. Preferably, a Jurkat line transfected with an expression vector encoding the CD16 receptor is used as effector cell. This line is particularly advantageous since it is immortalized and develops indefinitely in culture media.
- Among the cytokines that may be quantified, it is possible to measure the production of at least one cytokine selected from IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, etc., TNFa, TGFβ, IP10 and IFNγ. The interleukin IL-2 may advantageously be chosen.
- The amount of cytokine produced is a marker for activation or for inhibition of effector cells.
- Preferably, the amount of interleukin IL2 secreted reflects the quality of the antibody bound by the CD16 receptor as regards its antigen-binding integrity (Fc function) and effectiveness (antigenic site). The measurement of the amount of IL2 is correlated with an ADCC-type activity.
- In another aspect, the invention relates to a method for evaluating the effectiveness of a monoclonal or polyclonal antibody, characterized in that it comprises bringing CD16 receptor-expressing effector cells of the immune system, which may or may not be transformed, into contact in a reaction medium in the presence of an antibody and of the antigen for said antibody, and measuring the amount of at least one cytokine produced by the CD16 receptor-expressing cell.
- This method is particularly suitable for evaluating the effectiveness of a monoclonal or polyclonal antibody having an anti-human red blood cell Rh D specificity.
- In another aspect, the invention relates to a method for evaluating the ability of a cell to produce an effective monoclonal antibody, characterized in that it comprises bringing CD16 receptor-expressing effector cells of the immune system, which may or may not be transformed, into contact in a reaction medium in the presence of an antibody and of the antigen for said antibody, and measuring the amount of at least one cytokine produced by the CD16 receptor-expressing cell.
- This method can be implemented for cells used for the production of therapeutic antibodies, such as CHO, YB2/0, human lymphoblastoid cells, insect cells and murine myeloma cells.
- This method may also be applied to the evaluation of MoAb production by transgenic plants or transgenic mammals.
- In a complementary aspect, the invention is directed toward a method for evaluating the effectiveness and the integrity of polyclonal antibodies after one or more purification steps, characterized in that it comprises bringing CD16 receptor-expressing effector cells of the immune system, which may or may not be transformed, into contact in a reaction medium in the presence of the purified antibody and of the antigen for said antibody, and measuring the amount of at least one cytokine produced by the CD16 receptor-expressing cell.
- The methods described above can optionally be carried out in the presence of human immunoglobulins (IVIgs).
- By way of example, antibodies for which an increase of more than 100%, 250%, 500% or 1000% in the amount of IL-2 release is observed compared with the control in the absence of antibody, or a given antibody as negative reference, will be selected.
- The invention is also directed toward the use of the method described above, for selecting antibodies that are effective for a therapeutic treatment. For example, the antibody selected may be an anti-D. It may also be intended for the treatment of autoimmune and inflammatory diseases, cancers and infections with pathogenic agents.
- The invention also relates to a kit for evaluating the biological activity of an antibody, comprising means and reagents required and CD16 receptor-expressing effector cells for carrying out the method described above making it possible to assay at least one cytokine, in particular IL-2, IFN and TNF.
- In addition, this assay may also comprise an ADCC assay. In this respect, the invention relates to a method for selecting an optimized chimeric, humanized or human monoclonal antibody, characterized in that it comprises bringing CD16 receptor-expressing cells into contact in a reaction medium in the presence of the antibody and of the antigen for said antibody, and measuring the amount of at least one cytokine produced by the CD16 receptor-expressing cell.
- In a particular embodiment, the antibody of the invention is capable of inducing the secretion of at least one cytokine by a leukocytic cell, in particular of the NK (natural killer) family, or by cells of the monocyte-macrophage group. In general, for selecting the antibodies, use is made of a Jurkat-type line or another line transfected with an expression vector encoding the Fc receptor, including CD16, CD32 and CD64, as effector cell. Preferably, for selecting the antibodies, a Jurkat line transfected with an expression vector encoding the CD16 receptor is used as effector cell. This line is particularly advantageous since it is immortalized and develops indefinitely in culture media. The amount of interleukin IL2 secreted reflects the quality of the antibody bound by the CD16 receptor as regards its antigen-binding integrity (Fc function) and effectiveness (antigenic site).
- In another embodiment, the optimized antibody can be prepared after having been purified and/or modified ex vivo by modification of the glycan structure of the Fc fragment. To this effect, any suitable chemical, chromatographic or enzymatic means can be used to modify the glycan structure of the antibodies.
- In another embodiment, the antibody can be produced by cells of rat myeloma lines, in particular YB2/0 and its derivatives. Other lines may be selected for their properties of producing the antibodies defined above.
- Human lymphoblastoid cells, insect cells and murine myeloma cells may, for example, be tested. The selection may also be applied to the evaluation of the antibodies produced by transgenic plants or transgenic mammals. To this effect, production in CHO serves as a reference (CHO being used for medicament antibody production) for comparing and selecting the production systems resulting in the antibodies according to the invention.
- The general glycan structure of antibodies is of the biantennary type, with short chains, a low degree of sialylation, nonintercalated terminal attachment point mannoses and GlcNAcs, and a low degree of fucosylation. In these antibodies, the intermediate GlcNAc content is non zero. For example, use may be made of compositions of antibodies having a content greater than 60%, preferably greater than 80% for the G0+G1+G0F+G1F forms, it being understood that the G0F+G1F forms are less than 50%, preferably less than 30%. These compositions can be obtained with rat myeloma lines, for example with the YB2/0 line.
- In a second aspect, the invention is directed toward the use of an antibody described above, for preparing a medicament intended to induce the secretion of at least one cytokine by an effector cell belonging to the immune system, said antibody being characterized in that it can be obtained by means of a method of selection comprising bringing CD16 receptor-expressing effector cells of the immune system, which may or may not be transformed, into contact in a reaction medium in the presence of the test antibody and of the antigen for said antibody, and measuring the amount of at least one cytokine produced by the CD16 receptor-expressing cell.
- Preferably, for selecting the antibodies, a Jurkat line transfected with an expression vector encoding the CD16 receptor is used as effector cell. Said released cytokines are interleukins, interferons and tissue necrosis factors (TNF). Thus, the antibody selected has the ability to induce the secretion of at least one cytokine chosen from IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, etc., TNFa, TGFβ, IP10 and IFNγ, by the CD16 receptor-expressing effector cells of the immune system.
- Preferably, the antibody selected has the ability to induce the secretion of IL-2 by the CD16 receptor-expressing effector cells of the immune system. The amount of interleukin IL2 secreted reflects the quality of the antibody bound by the CD16 receptor as regards its antigen-binding integrity (Fc function) and effectiveness (antigenic site). The measurement of the amount of IL2 is correlated with an ADCC-type activity.
- The selection can take place on antibodies produced by cells commonly used for the production of therapeutic antibodies, such as CHO, YB2/0, human lymphoblastoid cells, insect cells and murine myeloma cells. The selection may also be applied to the evaluation of antibodies produced by transgenic plants or transgenic mammals.
- Preferably, the invention is directed toward the use of an antibody produced by a rat myeloma line, for example with the YB2/0 line, for preparing a medicinal product intended to induce the secretion of at least one cytokine by an effector cell belonging to the immune system. In this respect, the invention relates to the use of an antibody having a biantennary-type glycan structure, with short chains, a low degree of sialylation, nonintercalated terminal attachment point mannoses and GlcNAcs and a low degree of fucosylation, for preparing a medicinal product intended to induce the secretion of at least one cytokine by an effector cell belonging to the immune system. In this antibody, the intermediate GlcNAc content is non zero. For example, use may be made of compositions of antibodies with a content of greater than 60%, preferably greater than 80% for the G0+G1+G0F+G1F forms, it being understood that the G0F+G1F forms are less than 50%, preferably less than 30%.
- In a particular embodiment, the antibody selected is capable of inducing the secretion of at least one cytokine by a leukocytic cell, in particular of the NK (natural killer) family, or by cells of the monocyte-macrophage group.
- The invention also relates to the use of the selected antibodies described above that are specific for an antigen which originates from a pathological cell or from an organism that is pathogenic for humans.
- This antibody is a monoclonal or polyclonal antibody.
- For example, the antibody is a monoclonal or polyclonal antibody having anti-human red blood cell Rhesus specificity.
- The antibody according to the invention may also be an antibody directed against viruses that are pathogenic for humans, against malignant tumor antigens or against the antigens of a bacterium or of a parasite that is pathogenic for humans.
- Advantageously, the antibody selected shows an increase of more than 100%, 250%, 500% or 1000% in the amount of IL-2 release compared with the control in the absence of antibody or in the presence of a given antibody as negative reference. The method described above can optionally be carried out in the presence of human immunoglobulins (IVIgs). For comparison, homologous antibodies produced in CHO cells, or else commercially available reference antibodies, may be used.
- In a supplementary aspect, the invention is directed toward the use of said selected antibodies as a therapeutic support in human medicine, in particular for producing a medicinal product intended for the treatment of autoimmune and inflammatory diseases, cancers and infections with pathogenic agents.
-
FIG. 1 : Description of the MNC ADCC assay - Mononuclear cells in the presence of Tegeline (IVIg) are incubated with the anti-Rhesus D antibodies and Rhesus+red blood cells (target). After an overnight period at 37° C., the red blood cell lysis is measured by evaluating the amount of hemoglobin released into the reaction medium.
-
FIG. 2 : Description of the NK ADCC assay - Purified NK cells are incubated with the anti-Rhesus D antibodies and Rhesus+red blood cells (target). After an overnight period at 37° C., the red blood cell lysis is measured by evaluating the amount of hemoglobin released into the reaction medium.
-
FIG. 3 : NK ADCC results and inhibition with the anti-CD16 “3G8” - The anti-D antibodies DF5-EBV (expressed by the EBV-immortalized B cell) and DF5-YB2/0 (expressed by the YB2/0 cell) are compared with the polyclonal antibody WinRho with respect to their ability to induce lysis of Rhesus D red blood cells in the presence of NK cells. The inhibition of the ADCC is studied in the presence of the anti-CD16 3G8.
-
FIG. 4 : Description of the Jurkat CD16 assay - Jurkat CD16 cells are mixed with various anti-D antibodies in the presence of Rhesus+red blood cells and of PMA. After an overnight incubation period, the release of IL-2 into the supernatant is quantified by ELISA.
-
FIG. 5 : Results of the Jurkat CD16 assay - Comments: the antibodies that are positive in ADCC-NK induce secretion of IL2 in the presence of Jurkat CD16 and of their target.
-
FIG. 6 : Release of cytokine (IL-2, IFN and TNF) by leukocytes that are antibody-activated in the presence of their target - A—Leukocyte activation scheme
- B—The leukocytes were incubated with various antibodies in the presence of red blood cells. After an overnight incubation period, the release of TNFa and IFNγ into the supernatant was quantified by ELISA.
-
FIG. 7 : Release of cytokine (IFN, TNF) by NK cells that are antibody-activated in the presence of their target (LFB-R297-RBC) - A—NK cell activation scheme.
- B—Purified NK cells were mixed with various anti-D antibodies in the presence of Rhesus+red blood cells. After an overnight incubation period, the release of TNFa and of IFNγ into the supernatant was quantified by ELISA.
-
FIG. 8 : Release of IL2 by Jurkat CD16 activated by an anti-CD20 - A—Jurkat cell activation scheme.
- B—Jurkat CD16 cells were mixed with various anti-CD20 antibodies (murine antibody CAT13 and chimeric antibody C273) in the presence of Raji cells and of PMA. After an overnight incubation period, the release of IL-2 into the supernatant was quantified by ELISA.
-
FIG. 9 : Release of IL2 by Jurkat CD16 activated by an anti-D - A—Jurkat cell activation scheme.
- B—Jurkat CD16 cells were mixed with various anti-D antibodies in the presence of Rhesus+red blood cells and of PMA. After an overnight incubation period, the release of IL-2 into the supernatant was quantified by ELISA. DF5 expressed in YB2/0 and T125 expressed in CHO Lec13 induce strong secretion of IL2.
-
FIG. 10 : Line of correlation between the ADCC (Tegeline 500 μg/well and anti-D at 7.5 ng/well) and the Jurkat IL2 assay. -
FIG. 11 : Secretion of IL-8 by mononuclear cells. -
FIG. 12 : Induction of TNF alpha, IL-6 and TGF beta secretion by mononuclear cells. -
FIG. 13 : Induction of cytokine secretion by polymorphonuclear cells. -
FIG. 14 : Induction of IFN gamma, TNF alpha and IP10 secretion by NK cells. - Antibodies:
- WinRho polyclonal antibodies, DF5-EBV monoclonal antibody, DF5-YB2/0 monoclonal antibody.
- Principle:
- This assay evaluates the ability of the anti-D antibodies to bind to the CD16 receptor (Fc gamma RIII) expressed on Jurkat CD16 cells, and to induce IL2 secretion.
- This assay consists in bringing the following into contact in a 96-well plate: the anti-D antibodies, the papain-treated Rhesus-positive red blood cells, the Jurkat CD16 cells and PMA.
- After an overnight incubation period at 37° C., the 96-well plates are centrifuged and the amount of secreted IL2 is assayed in the supernatant.
- Material
- Positive control antibodies: Poly-D WinRho, DF5-YB2/0.
- Negative control antibody: DF5.
- Rhesus-positive red blood cells.
- Jurkat CD16 cells.
- IL2 assay kit: Quantikine from R/D.
- Method
- Treatment of red blood cells with papain.
- 1 ml of pellet of red blood cells diluted in PBS is incubated with 1 ml of a papain solution (1 mg/ml) for 10 min at 37° C. Three washes are then carried out in H2O-0.15M NaCl.
- Reaction mixture:
-
- Antibody: 50 μl of a dilution to 150 ng/ml in IMDM 5% SVF,
- PMA: 50 μl of a dilution to 40 ng/ml in IMDM 5% SVF,
- red blood cells treated with papain. 50 μl at 8×106/ml in IMDM 5% SVF,
- Jurkat CD16. 50 μl at 2×106/ml in IMDM 5% SVF.
- Overnight incubation at 37° C.
- Then, centrifugation of the plates, removal of 100 μl of supernatants and assaying of IL2 with the commercial kit. Reading at 450 nm.
- The values (in pg/ml) are given in the form of a histogram for each sample.
- For this study, 3 anti-D monoclonal antibodies were compared.
- The Mab DF5-EBV was produced by human B lymphocytes obtained from a D-negative immunized donor, and immortalized by transformation with EBV. This antibody was used as a negative control given that it was shown to be incapable of eliminating Rhesus-positive red blood cells from the circulation in a clinical trial.
- The monoclonal antibody (Mab) DF5-YB2/0 was obtained by expressing the primary sequence of DF5-EBV in the YB2/0 line. The monoclonal antibody R297 and other recombinant antibodies were also expressed in YB2/0.
- These antibodies were assayed in vitro for their ability to induce lysis of papain-treated red blood cells using mononuclear cells (PBLs) as effector.
- All the assays were carried out in the presence of human immunoglobulins (IVIgs) so as to reconstitute the physiological conditions.
- It is thought that IVIgs bind with high affinity to FcgammaRI (CD64). The two Mabs DF5-YB2/0 and R297 induce red blood cell lysis at a level comparable with that of the WinRho antibodies. On the other hand, the Mab DF5-EBV is completely ineffective.
- In a second series of experiments, purified NK cells and untreated red blood cells were used as effectors and targets, respectively. After incubation for 5 hours, the anti-D Mabs R297 and DF5-YB2/0 were shown to be capable of causing red blood cell lysis, whereas DF5-EBV remained ineffective.
- In these two experiments, the red blood cell lysis was inhibited by the antibody 3G8 directed against FcgammaRIII (CD16).
- In summary, these results demonstrate that the ADCC brought about by the antibody R297 and the antibody DF5-YB2/0 involves FcgammaRIII expressed at the surface of the NK cells.
- In the context of the invention, a third series of experiments showed the value of an in vitro assay using Jurkat CD16 cells to evaluate the effectiveness of anti-D antibodies. The antibodies were incubated overnight with Rhesus-positive red blood cells and Jurkat CD16 cells. The release of IL-2 into the supernatant was evaluated by ELISA. A strong correlation between ADCC and activation of the Jurkat cells was observed, which implies that this assay can be used to discriminate between anti-D antibodies as a function of their reactivity toward FcgammaRIII (CD16).
- The same samples are evaluated by ADCC and in the Jurkat IL2 assay. The results are expressed as percentage of the reference antibody “LFB-R297”. The curve for correlation between the two techniques has a coefficient of r2=0.9658 (
FIG. 10 ). - In conclusion, these data show the importance of post-translational modifications of the structure of the antibodies in terms of their FcgammaRIII-specific ADCC activity. The release of cytokines such as IL-2 reflects this activity.
- Study model: NK cells purified from peripheral blood.
- Applications: enhancement of an anti-tumor response.
- IL2 induces activation of T lymphocytes and of the NK cells themselves, which can go as far as stimulation of cell proliferation. IFNγ stimulates the activity of CTLs and can enhance the activity of macrophages.
- Applications: Enhancement of phagocytosis and induction of anti-inflammatory properties. TNF stimulates the proliferation of tumor-infiltrating lymphocytes and macrophages. IL-1Ra is a cytokine produced by macrophages which compete with IL1 at the level of its receptor and thus exerts an anti-inflammatory effect.
- Applications: Induction of tolerance specific to certain antigens. IL10 is a molecule that inhibits the activation of various effector cells and the production of cytokines.
- Three cell populations were studied: polymorphonuclear cells, mononuclear cells and NK cells. The cytokine syntheses are dependent on the presence of the target. There are few differences in the cytokine profiles induced by the antibody R297 and the polyclonal anti-D antibody. AD1 very often does not induce cytokine secretion.
- Results:
- 6.1 The monoclonal antibody R297 and the polyclonal antibody WinRho induce considerable secretion of IL8 in the presence of mononuclear cells. This secretion is dependent on the antibody concentration and on the presence of the antigenic target. The antibody AD1 is much less effective (
FIG. 11 ), i.e. less capable of inducing the production of cytokines. - With mononuclear cells (MNCs), the monoclonal antibody R297 and the polyclonal antibody WinRho induce considerable secretion of TNF alpha, and, to a lesser degree, although greater than AD1, secretion of IL6, of IFN gamma, of IP10, of TNF alpha and of TGF beta. At the highest antibody concentration, this secretion of IL6, IFN gamma and IP10 increases, but it decreases for TNF alpha and TGF beta (
FIG. 12 ). - 6.2 The monoclonal antibody R297 and the polyclonal antibody WinRho induce a very weak, but greater than AD1, secretion of IL2, of IFN gamma, of IP10 and of TNF by polymorphonuclear cells. This secretion is antibody-concentration dependent (
FIG. 13 ). - 6.3 The monoclonal antibody R297 and the polyclonal antibody WinRho induce considerable secretion of IFN gamma, of IP10 and of TNF by NK cells. This secretion is antibody-concentration dependent (
FIG. 14 ). - Introduction
- Our first results showed that the anti-D antibodies produced in YB2/0 and also the polyclonal antibodies used clinically induced the production of cytokines, in particular of TNF alpha and of interferon gamma (IFN gamma) from purified NK cells or from mononuclear cells. On the other hand, other anti-D antibodies, produced in other cell lines, are negative in ADCC and proved to be incapable of inducing this secretion.
- The additional results below show that this mechanism is not exclusive to the anti-D antibodies in the presence of Rhesus-positive red blood cells, but also applies to the anti-CD20 and anti-HLA-DR antibodies expressed in YB2/0. Expression in CHO confers less substantial activating properties on the antibody. This is in correlation with the results obtained by ADCC.
- Materials
- Antibodies.
-
- Anti-CD20: the chimeric anti-CD20 antibody transfected into YB2/0 is compared with a commercial anti-CD20 antibody produced in CHO (Rituxan).
- Anti-HLA-DR: the same sequence encoding the chimeric anti-HLA-DR antibody is transfected into CHO (B11) or YB2/0 (4B7).
- Target cells: Raji cells expressing at their surface the CD20 and HLA-DR antigens.
- Effector cells: human NK cells purified by negative selection from a human blood bag.
- Method
- Various concentrations of anti-CD20 or anti-HLA-DR antibodies are incubated with Raji cells (targets) and NK cells (effectors). After incubation for 16 hours, the cells are centrifuged. The supernatants are assayed for TNF alpha and IFN gamma.
- Results:
- 7.1 TNF alpha: The results are expressed in pg/ml of TNF alpha assayed in the supernatants. The various concentrations of antibodies added to the reaction mixture are given along the X-axis (
FIG. 15 ). - The chimeric anti-CD20 and anti-HLA-DR antibodies produced in YB2/0 induce higher levels of TNF in the presence of their target (Raji) compared with the same antibodies produced in CHO. The amount of TNF alpha is clearly dose-dependent on the concentration of antibody added. At 10 mg/ml of antibody, five times more TNF alpha is induced with the antibodies produced in YB2/0 compared with the antibodies produced in CHO.
- 7.2 IFN gamma: The results are expressed in pg/ml of IFN gamma assayed in the supernatants. The various concentrations of antibodies added to the reaction mixture are given along the X-axis (
FIG. 16 ). - The chimeric anti-CD20 and anti-HLA-DR antibodies produced in YB2/0 induce higher levels of IFN gamma in the presence of their target (Raji) compared with the same antibodies produced in CHO. The amount of IFN gamma is clearly dose-dependent on the concentration of antibody added. At all the concentrations used (0 to 200 ng/ml), the anti-HLA-DR antibody produced in CHO induces no secretion of IFN gamma, whereas 40 ng/ml of the antibody produced in YB2/0 induces approximately 1000 pg/ml of IFN gamma.
- For the anti-CD20 antibody, less than 10 ng/ml of the antibody produced in YB2/0, and 200 ng/ml of the antibody produced in CHO, are required to induce 300 pg/ml of IFN gamma (
FIG. 16 ). -
- Jefferis, R., Lund, J., Mizutani, H., Nakagawa, H., Kawazoe, Y., Arata, Y. and Takahashi, N. A comparative study of the N-linked oligosaccharides structure of human IgG Subclass proteins. Biochem. J., 268:529-537 (1990).
- Leatherbarrow, R. J., Rademacher, T. W., Dwek, R. A., Woof, J. M., Clark, A., Burton, D. R., Richardson, N. and Feinstein, A. Effector functions of monoclonal aglycosylated mouse IgG2a; binding and activation of complement component C1 and interaction with human Fc receptor. Molec. Immun. 22, 407-415 (1985).
- Lund, J., Tanaka, T., Takahashi, N., Sarmay, G., Arata, Y. and Jefferis, R. A protein structural change in aglycosylated IgG3 correlates with loss of hu Fcγ RI and hu FcγRIII binding and/or activation. Molec. Immun. 27, 1145-1153 (1990).
- Parekh, R. B., Dwek, R. A., Sutton, B. J., Fernandes, D. L., Leung, A., Stanworth, D., Rademacher, T. W., Mizuochi, T., Taniguchi, T., Matsuta, K., Takeuchi, F., Nagano, Y., Miyamoto, T. and Kobata, A. Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. Nature, 316:452-457 (1985).
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/585,900 US20100323368A1 (en) | 2002-09-13 | 2009-09-28 | Cytokine production-inducing antibody |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0211415A FR2844520B1 (en) | 2002-09-13 | 2002-09-13 | USE OF ANTIBODY INDUCING THE SECRETION OF CYTOKINES IN THERAPY |
FR02/11415 | 2002-09-13 | ||
FR0211416 | 2002-09-13 | ||
FR0211416A FR2844521B1 (en) | 2002-09-13 | 2002-09-13 | MEASUREMENT OF THE PRODUCTION OF CYTOKINES AS A MARKER FOR ACTIVATION OF EFFECTOR CELLS |
PCT/FR2003/002715 WO2004024768A2 (en) | 2002-09-13 | 2003-09-15 | Cytokine production-inducing antibody |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/585,900 Continuation US20100323368A1 (en) | 2002-09-13 | 2009-09-28 | Cytokine production-inducing antibody |
Publications (2)
Publication Number | Publication Date |
---|---|
US20050249732A1 true US20050249732A1 (en) | 2005-11-10 |
US7595165B2 US7595165B2 (en) | 2009-09-29 |
Family
ID=31995630
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/527,665 Expired - Fee Related US7595165B2 (en) | 2002-09-13 | 2003-09-15 | Method of measuring activation of effector cells |
US12/585,900 Abandoned US20100323368A1 (en) | 2002-09-13 | 2009-09-28 | Cytokine production-inducing antibody |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/585,900 Abandoned US20100323368A1 (en) | 2002-09-13 | 2009-09-28 | Cytokine production-inducing antibody |
Country Status (9)
Country | Link |
---|---|
US (2) | US7595165B2 (en) |
EP (2) | EP1537419B1 (en) |
JP (1) | JP4368800B2 (en) |
AT (1) | ATE511654T1 (en) |
AU (1) | AU2003282161B2 (en) |
CA (1) | CA2498315C (en) |
DK (1) | DK1537419T3 (en) |
IL (1) | IL167385A (en) |
WO (1) | WO2004024768A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090053233A1 (en) * | 2004-12-15 | 2009-02-26 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Cytotoxic Antibody Directed Against Type B Lymphoid Hematopoietic Proliferations |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1537419B1 (en) * | 2002-09-13 | 2011-06-01 | LFB Biotechnologies | Test for CD16-mediated ADCC efficacy of monoclonal or polyclonal antibodies |
FR2895086B1 (en) * | 2005-12-16 | 2012-10-05 | Lab Francais Du Fractionnement | POTENTIATION OF APOPTOSIS BY MONOCLONAL ANTIBODIES |
ATE501436T1 (en) * | 2006-09-13 | 2011-03-15 | Glycode | METHOD FOR STUDYING THE RESPONSE TO TREATMENT WITH A MONOCLONAL ANTIBODY |
FR2968561B1 (en) † | 2010-12-13 | 2013-08-09 | Lfb Biotechnologies | USE OF ANTIBODY AGAINST A MEMBRANE PROTEIN |
FR3064007A1 (en) | 2017-03-20 | 2018-09-21 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | ANTIBODIES FOR THE TREATMENT OF CANCERS |
EP3924368A4 (en) * | 2019-02-14 | 2022-12-14 | Research Institute at Nationwide Children's Hospital | Use of a stimulating agent to assay immune cell potency |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU4070500A (en) * | 1999-04-05 | 2000-10-23 | Biocrystal Limited | Assay kits and methods for immune complex-mediated activation involving shed antigens |
FR2807767B1 (en) * | 2000-04-12 | 2005-01-14 | Lab Francais Du Fractionnement | MONOCLONAL ANTIBODIES ANTI-D |
HUP0600342A3 (en) * | 2001-10-25 | 2011-03-28 | Genentech Inc | Glycoprotein compositions |
EP1537419B1 (en) * | 2002-09-13 | 2011-06-01 | LFB Biotechnologies | Test for CD16-mediated ADCC efficacy of monoclonal or polyclonal antibodies |
-
2003
- 2003-09-15 EP EP03773780A patent/EP1537419B1/en not_active Expired - Lifetime
- 2003-09-15 CA CA2498315A patent/CA2498315C/en not_active Expired - Fee Related
- 2003-09-15 JP JP2004535611A patent/JP4368800B2/en not_active Expired - Fee Related
- 2003-09-15 WO PCT/FR2003/002715 patent/WO2004024768A2/en active Application Filing
- 2003-09-15 EP EP09152731A patent/EP2092939A3/en not_active Withdrawn
- 2003-09-15 US US10/527,665 patent/US7595165B2/en not_active Expired - Fee Related
- 2003-09-15 AU AU2003282161A patent/AU2003282161B2/en not_active Ceased
- 2003-09-15 DK DK03773780.6T patent/DK1537419T3/en active
- 2003-09-15 AT AT03773780T patent/ATE511654T1/en active
-
2005
- 2005-03-10 IL IL167385A patent/IL167385A/en active IP Right Grant
-
2009
- 2009-09-28 US US12/585,900 patent/US20100323368A1/en not_active Abandoned
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090053233A1 (en) * | 2004-12-15 | 2009-02-26 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Cytotoxic Antibody Directed Against Type B Lymphoid Hematopoietic Proliferations |
US9234045B2 (en) | 2004-12-15 | 2016-01-12 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Monoclonal antibody directed against CD20 antigen |
US9873745B2 (en) | 2004-12-15 | 2018-01-23 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Antibody method for treatment of a disease in which the target cells are cells which express CD20 |
Also Published As
Publication number | Publication date |
---|---|
IL167385A (en) | 2012-08-30 |
JP4368800B2 (en) | 2009-11-18 |
ATE511654T1 (en) | 2011-06-15 |
US20100323368A1 (en) | 2010-12-23 |
WO2004024768A3 (en) | 2004-09-30 |
EP2092939A3 (en) | 2011-12-21 |
JP2006517087A (en) | 2006-07-20 |
AU2003282161A1 (en) | 2004-04-30 |
CA2498315C (en) | 2013-01-29 |
EP2092939A2 (en) | 2009-08-26 |
AU2003282161B2 (en) | 2010-06-24 |
CA2498315A1 (en) | 2004-03-25 |
US7595165B2 (en) | 2009-09-29 |
EP1537419B1 (en) | 2011-06-01 |
WO2004024768A2 (en) | 2004-03-25 |
EP1537419A2 (en) | 2005-06-08 |
DK1537419T3 (en) | 2011-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6124958B2 (en) | Anti-D monoclonal antibody | |
AU2004283924B2 (en) | Correlation between the fucose content / galactose content ratio of anti-rhesus-D and anti-HLA-DR antibodies and the ADCC activity | |
US20100323368A1 (en) | Cytokine production-inducing antibody | |
US20050271652A1 (en) | Treatment of pathologies which escape the immune response, using optimised antibodies | |
US10308970B2 (en) | Methods for controlling fucosylation levels in proteins | |
JP2009501913A (en) | Efficacy assays for antibody drug substances that bind to Fc receptors | |
ES2362652T3 (en) | PROCEDURE FOR EVALUATING THE EFFECTIVENESS ADCC MEDIATED BY THE CD16 OF MONOCLONAL OR POLYCLONAL ANTIBODIES. | |
FR2844521A1 (en) | Measuring activation of immune system effector cells, useful e.g. for selecting antibodies for therapy, by measuring cytokine release in presence of antibody and its antigen | |
AU2016204535C1 (en) | Anti-D monoclonal antibodies | |
AU2014208242B2 (en) | Anti-D monoclonal antibodies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOT Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DE ROMEUF, CHRISTOPHE;GAUCHER, CHRISTINE;GLACET, ARNAUD;AND OTHERS;REEL/FRAME:017319/0908;SIGNING DATES FROM 20051109 TO 20051202 |
|
AS | Assignment |
Owner name: LFB BIOTECHNOLOGIES, FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES;REEL/FRAME:022378/0106 Effective date: 20080120 Owner name: LFB BIOTECHNOLOGIES,FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES;REEL/FRAME:022378/0106 Effective date: 20080120 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
AS | Assignment |
Owner name: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOT Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:LFB BIOTECHNOLOGIES;REEL/FRAME:031931/0561 Effective date: 20140102 |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
FEPP | Fee payment procedure |
Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
LAPS | Lapse for failure to pay maintenance fees |
Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20210929 |